Related references
Note: Only part of the references are listed.CIP2A is Overexpressed in Non-Small Cell Lung Cancer and Correlates with Poor Prognosis
Qian-Ze Dong et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer
C. Bockelman et al.
BRITISH JOURNAL OF CANCER (2011)
ETS1 Mediates MEK1/2-Dependent Overexpression of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A) in Human Cancer Cells
Anchit Khanna et al.
PLOS ONE (2011)
Helicobacter pylori CagA upregulation of CIP2A is dependent on the Src and MEK/ERK pathways
Dapeng Zhao et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2010)
CIP2A Is Associated with Human Breast Cancer Aggressivity
Christophe Come et al.
CLINICAL CANCER RESEARCH (2009)
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Anchit Khanna et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Mechanisms of MYC stabilization in human malignancies
Melissa R. Junttila et al.
CELL CYCLE (2008)
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Keren Levanon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Early events in the pathogenesis of epithelial ovarian cancer
Charles N. Landen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The cell of origin of ovarian epithelial tumours
Louis Dubeau
LANCET ONCOLOGY (2008)
Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies
Martin Koebel et al.
PLOS MEDICINE (2008)
CIP2A inhibits PP2A in human malignancies
Melissa R. Junttila et al.
CELL (2007)
PP2A: Unveiling a reluctant tumor suppressor
Marc Mumby
CELL (2007)
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma
Heini Lassus et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2006)
Molecular pathogenesis of ovarian borderline tumors: New insights and old challenges
IM Shih et al.
CLINICAL CANCER RESEARCH (2005)
Global cancer statistics, 2002
DM Parkin et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2005)
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis -: A mutational analysis with immunohistochemical correlation
G Singer et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2005)
Elevated cyclooxygenase-2 expression is associated with altered expression of p53 and SMAD4, amplification of HER-2/neu, and poor outcome in serous ovarian carcinoma
TL Erkinheimo et al.
CLINICAL CANCER RESEARCH (2004)
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2004)
Ovarian tumorigenesis - A proposed model based on morphological and molecular genetic analysis
IM Shih et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Distinct subtypes of serous ovarian carcinoma identified by p53 determination
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2003)
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer
LS Hoo et al.
ONCOGENE (2002)
Tissue microarrays for rapid linking of molecular changes to clinical endpoints
J Torhorst et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Tissue microarray technology for high-throughput molecular profiling of cancer
OP Kallioniemi et al.
HUMAN MOLECULAR GENETICS (2001)
Histopathologic grading of ovarian carcinoma: A review and proposal
SG Silverberg
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2000)
Share Paper
